Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Christopher Lynch

Postdoctoral Researcher

I am an early-career postdoc, being awarded a PhD from the Centre for Haematology, Department of Medicine, Imperial College in June 2017. My thesis was focused on using recombinant proteins to understand the mechanisms that regulate the haemostatic functions of the plasma protein von Willebrand Factor and resulted in a number of publications.

I am currently working in Prof. Bhattacharya’s lab in RDM Division of Cardiovascular Medicine, University of Oxford. The focus has been on the recombinant production of chemokine-inhibiting proteins from ticks, firstly to determine underlying mechanisms of chemokine inhibition and second, also to support pre-clinical research projects. 

I have been awarded ‘Young Investigator Awards’ for conference abstracts submitted to the International Society of Thrombosis and Haemostasis (2015) and the European Cell Migration and Chemokine conference (2019).



1. Lee AW*, Deruaz M*, Lynch C*, Davies G*, Singh K, Alenazi Y, Eaton JRO, Kawamura A, Shaw J, Proudfoot AEI, Dias JM, Bhattacharya S. A knottin scaffold directs the CXC-chemokine-binding specificity of tick evasins. J Biol Chem. 2019 Jul 19;294(29):11199-11212. doi: 10.1074/jbc.RA119.008817. Epub 2019 Jun 5. PMID: 31167786; PMCID: PMC6643034.

(*joint first authors)


2. Lynch CJ, Lane DA. N-linked glycan stabilization of the VWF A2 domain. Blood. 2016 Mar 31;127(13):1711-8. doi: 10.1182/blood-2015-09-672014. Epub 2016 Jan 14. PMID: 26773038; PMCID: PMC4817312.

3. Lynch CJ, Cawte AD, Millar CM, Rueda D, Lane DA. A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct. PLoS One. 2017 Nov 29;12(11):e0188405. doi: 10.1371/journal.pone.0188405. PMID: 29186156; PMCID: PMC5706690.


4. Lynch CJ, Lane DA, Luken BM. Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF. Blood. 2014 Apr 17;123(16):2585-92. doi: 10.1182/blood-2013-11-538173. Epub 2014 Feb 20. PMID: 24558203; PMCID: PMC3990914.

5. Rye CS, Chessum NE, Lamont S, Pike KG…et al….Lynch CJ, Sharp SY.... et al…..Foote KM, Green S, Workman P, Jones K. Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. Medchemcomm. 2016 Aug 1;7(8):1580-1586. doi: 10.1039/c6md00159a. Epub 2016 Jun 13. PMID: 27746890; PMCID: PMC5048338.